[:en]
Abstract
In recent years, there have been major advances in our understanding of the mechanisms underlying fibrosis progression and regression, and how coordinated interactions between parenchymal and non-parenchymal cells impact on the fibrogenic process. Recent studies have highlighted that metabolic reprogramming of parenchymal cells, immune cells (immunometabolism) and hepatic stellate cells is required to support the energetic and anabolic demands of phenotypic changes and effector functions. In this review, we summarise how targeting cell-intrinsic metabolic modifications of the main fibrogenic cell actors may impact on fibrosis progression and we discuss the antifibrogenic potential of metabolically targeted interventions.
[:]
Other publications
01 Jul 2021
Authors :
Richard Moreau,
[:fr]Bin Gao[:],
[:fr]Maria Papp[:],
[:fr]Rafael Bañares[:],
[:fr]Patrick S Kamath[:],
Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF
[:fr]Front Immunol.[:]
05 Feb 2021
Authors :
Emmanuel Weiss,
Pierre de la Grange,
Mylène Defaye,
Juan José Lozano,
Ferrán Aguilar,
Pushpa Hegde,
Ariane Jolly,
Lucile Moga,
Sukriti Sukriti,
Banwari Agarwal,
Haqeeqat Gurm,
Marion Tanguy,
Johanne Poisson,
Joan Clària,
Paer-Selim Abback,
Axel Perianin,
Gautam Mehta,
Rajiv Jalan,
Claire Francoz,
Pierre-Emmanuel Rautou,
Sophie Lotersztajn,
Vicente Arroyo,
François Durand,
Richard Moreau,
LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling.
Sci Transl Med
15 Apr 2020
Authors :
Jinghong Wan,
Emmanuel Weiss,
Mkaddem Sanae Ben,
Morgane Mabire,
[:en]Pierre-Marie Choinier[:],
[:en] Olivia Picq[:],
[:en]Tristan Thibault-Sogorb[:],
[:en]Pushpa Hegde[:],
[:en]Dorsa Pishvaie[:],
Marcelle Bens,
[:en]Linda Broer[:],
Hélène Gilgenkrantz,
Richard Moreau,
Loredana Saveanu,
[:en]Patrice Codogno[:],
Renato Monteiro,
Sophie Lotersztajn,